US EditionAnnJi Pharmaceutical Company Announces Positive Phase 1/2a Results for AJ201 in Spinal and Bulbar Muscular Atrophy (SBMA) Patients
- On May 21, 2025, AnnJi Pharmaceutical reported favorable outcomes from its Phase 1/2a clinical study of AJ201, conducted in adult patients diagnosed with Spinal and Bulbar Muscular Atrophy.
- The randomized, double-blind, placebo-controlled study in six US sites tested AJ201’s safety, pharmacokinetics, and pharmacodynamics in SBMA patients.
- After 12 weeks of treatment, participants receiving AJ201 demonstrated notable enhancements in muscle and physical function, with an average improvement of 17.6 meters on the 6-Minute Walk Test and a 0.8-point rise in their SBMA Functional Rating Scale scores.
- Dr. Christopher Grunseich highlighted that the observed results provide strong evidence supporting the effectiveness of AJ201, noting improvements that were not seen in the placebo group.
- These results support AJ201’s continued development, with AnnJi planning Phase 3 trials to deliver a much-needed treatment for SBMA, which presently lacks FDA-approved options.
Insights by Ground AI
Does this summary seem wrong?
60 Articles
60 Articles
All
Left
5
Center
19
Right
8
AnnJi Pharmaceutical Company Announces Positive Phase 1/2a Results for AJ201 in Spinal and Bulbar Muscular Atrophy (SBMA) Patients
TAIPEI, May 21, 2025 /PRNewswire/ -- AnnJi Pharmaceutical Co., Ltd., a clinical-stage Taiwanese biotechnology company focused on addressing unmet medical needs in dermatology, neurology, and rare diseases, today announced positive results from its Phase 1/2a randomized, double-blind, placebo-controlled, first-in-patient clinical…
AnnJi reports outcomes from trial of spinal bulbar muscular atrophy therapy
AnnJi Pharmaceutical has reported encouraging outcomes from its randomised, placebo-controlled Phase I/IIa trial of AJ201.The post AnnJi reports outcomes from trial of spinal bulbar muscular atrophy therapy appeared first on Clinical Trials Arena.
Coverage Details
Total News Sources60
Leaning Left5Leaning Right8Center19Last UpdatedBias Distribution59% Center
Bias Distribution
- 59% of the sources are Center
59% Center
L 16%
C 59%
R 25%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
